

Laurence W Busse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5537090/publications.pdf>

Version: 2024-02-01

46
papers

3,082
citations

394421

19
h-index

345221

36
g-index

47
all docs

47
docs citations

47
times ranked

2791
citing authors

#	ARTICLE	IF	CITATIONS
1	Angiotensin II for the Treatment of Vasodilatory Shock. <i>New England Journal of Medicine</i> , 2017, 377, 419-430.	27.0	591
2	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2043.	7.4	458
3	Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. <i>BMJ, The</i> , 2022, 376, e069761.	6.0	393
4	Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. <i>Critical Care Medicine</i> , 2018, 46, 949-957.	0.9	186
5	Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 742.	7.4	168
6	Management of Refractory Vasodilatory Shock. <i>Chest</i> , 2018, 154, 416-426.	0.8	157
7	Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 1515-1524.	5.8	144
8	Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. <i>Critical Care</i> , 2014, 18, 534.	5.8	138
9	Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1253-1261.	5.6	101
10	Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options. <i>Critical Care</i> , 2020, 24, 36.	5.8	97
11	COVID-19 and the RAAS—a potential role for angiotensin II?. <i>Critical Care</i> , 2020, 24, 136.	5.8	84
12	Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. <i>Critical Care</i> , 2020, 24, 43.	5.8	69
13	The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. <i>Trials</i> , 2019, 20, 197.	1.6	57
14	Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. <i>Critical Care Medicine</i> , 2017, 45, 1285-1294.	0.9	52
15	Angiotensin in Critical Care. <i>Critical Care</i> , 2018, 22, 69.	5.8	46
16	The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. <i>Critical Care</i> , 2017, 21, 324.	5.8	44
17	Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. <i>Annals of Intensive Care</i> , 2019, 9, 63.	4.6	36
18	The use of angiotensin II in distributive shock. <i>Critical Care</i> , 2016, 20, 137.	5.8	26

#	ARTICLE	IF	CITATIONS
19	mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2022, 226, 797-807.	4.0	25
20	Vasopressor Therapy and Blood Pressure Management in the Setting of Acute Kidney Injury. <i>Seminars in Nephrology</i> , 2019, 39, 462-472.	1.6	22
21	Angiotensin II: a new therapeutic option for vasodilatory shock. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1287-1298.	2.0	21
22	Submassive Pulmonary Embolism. <i>Critical Care Clinics</i> , 2014, 30, 447-473.	2.6	19
23	New strategies to optimize renal haemodynamics. <i>Current Opinion in Critical Care</i> , 2020, 26, 536-542.	3.2	14
24	Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021. <i>Journal of Infectious Diseases</i> , 2022, 225, 1694-1700.	4.0	14
25	Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. <i>Clinical Infectious Diseases</i> , 2022, 75, S159-S166.	5.8	13
26	Angiotensin II in Vasodilatory Shock. <i>Critical Care Clinics</i> , 2019, 35, 229-245.	2.6	12
27	Successful Treatment of Antihypertensive Overdose Using Intravenous Angiotensin II. <i>Journal of Emergency Medicine</i> , 2019, 57, 339-344.	0.7	10
28	Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data. <i>Journal of Critical Care</i> , 2019, 50, 188-194.	2.2	10
29	Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 145-151.	0.5	10
30	Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. <i>Clinical Infectious Diseases</i> , 2023, 76, e460-e468.	5.8	9
31	Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. <i>Trials</i> , 2019, 20, 670.	1.6	7
32	Angiotensin II. <i>Critical Care Medicine</i> , 2019, 47, e436.	0.9	3
33	Protocol Compliance Guiding Angiotensin II Use in Post Cardiovascular Surgery Vasoplegia. , 2022, 4, e0687.		3
34	Response. <i>Chest</i> , 2019, 155, 242-243.	0.8	2
35	Sepsis Updates: Unpackaging the New Bundles. <i>International Anesthesiology Clinics</i> , 2019, 57, 3-16.	0.8	2
36	Minding the Gap: A Comparison of the Albumin-Lactate-Phosphate Corrected Anion Gap (ALPCAG) to the Strong Ion Gap (SIG). <i>Chest</i> , 2011, 140, 1012A.	0.8	1

#	ARTICLE	IF	CITATIONS
37	In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol. <i>Trials</i> , 2020, 21, 351.	1.6	1
38	Side Effects and Adverse Events Associated With Intravenous Angiotensin II in Humans: A Systematic Review and Meta-analysis. <i>Chest</i> , 2015, 148, 348A.	0.8	0
39	Just a Little Off the Top, Please*. <i>Critical Care Medicine</i> , 2019, 47, 1810-1813.	0.9	0
40	115: TRANSITION FROM HOSPITALIST-MANAGED TO INTENSIVIST-MANAGED COMMUNITY ICU. <i>Critical Care Medicine</i> , 2020, 48, 40-40.	0.9	0
41	1708: EVALUATION OF HYDROXOCOBALAMIN COMPARED TO METHYLENE BLUE FOR VASOPLEGIA POST-CARDIOTHORACIC SURGERY. <i>Critical Care Medicine</i> , 2020, 48, 829-829.	0.9	0
42	1104: Improvement in Protocol Compliance Through a Comprehensive Plan Guiding Angiotensin II Use. <i>Critical Care Medicine</i> , 2021, 49, 553-553.	0.9	0
43	39: Improvement in Mortality Linked to Protocol Compliance Guiding Angiotensin II Use. <i>Critical Care Medicine</i> , 2021, 49, 20-20.	0.9	0
44	1276: Decrease in Mortality With Protocol Compliance in Angiotensin II Use in the Cardiovascular ICU. <i>Critical Care Medicine</i> , 2021, 49, 644-644.	0.9	0
45	1500: ANGIOTENSIN II FOR DISTRIBUTIVE SHOCK IN PATIENTS WITH DURABLE LEFT VENTRICULAR ASSIST DEVICES. <i>Critical Care Medicine</i> , 2022, 50, 754-754.	0.9	0
46	441: THE EFFECT OF ANGIOTENSIN II IN VENOVENOUS VERSUS VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION. <i>Critical Care Medicine</i> , 2022, 50, 210-210.	0.9	0